4-(4-硝基苯氧基)苯甲醛 | 50961-54-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-硝基苯氧基)苯甲醛
• 中文别名: 4-(4-硝基苯氧基)-苯甲醛
• 英文名称: 4-(4-nitrophenoxy)benzaldehyde
• CAS: 50961-54-1
• 化学式: C₁₃H₉NO₄
• mdl: MFCD06496623
• 分子量: 243.219
• InChiKey: OCHOSUFDGPHRJA-UHFFFAOYSA-N

物化性质

• 熔点：
  106-110 °C
• 沸点：
  386.1±22.0 °C(Predicted)
• 密度：
  1.325±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi,N
• 安全说明：
  S26,S36/39,S60,S61
• 危险类别码：
  R50/53,R41,R43
• 海关编码：
  2913000090
• WGK Germany：
  3
• 危险品运输编号：
  UN 3077 9/PG 3
• 储存条件：
  室温、密封、干燥保存。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 4-(4-Nitrophenoxy)benzaldehyde
CAS-No. : 50961-54-1

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Serious eye damage (Category 1)
Skin sensitization (Category 1)
Acute aquatic toxicity (Category 1)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Risk of serious damage to eyes. May cause sensitization by skin contact. Very toxic to aquatic organisms,
may cause long-term adverse effects in the aquatic environment.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
May cause an allergic skin reaction.
Causes serious eye damage.
Very toxic to aquatic life.
Precautionary statement(s)
Avoid release to the environment.
Wear protective gloves/ eye protection/ face protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R41 Risk of serious damage to eyes.
R43 May cause sensitization by skin contact.
R50/53 Very toxic to aquatic organisms, may cause long-term adverse effects in
the aquatic environment.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36/39 Wear suitable protective clothing and eye/face protection.
S60 This material and its container must be disposed of as hazardous waste.
S61 Avoid release to the environment. Refer to special instructions/ Safety
data sheets.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C13H9NO4
Molecular Weight : 243,21 g/mol
Component Concentration
4-(4-Nitrophenoxy)benzaldehyde
CAS-No. 50961-54-1 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Air sensitive. Store under inert gas.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 106 - 110 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,818
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Oxidizing agents, Strong bases, Strong reducing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
May cause allergic skin reaction.
The preceding data, or interpretation of data, was determined using Quantitative Structure Activity
Relationship (QSAR) modeling.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes Causes eye burns.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
Very toxic to aquatic life.

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 3077 IMDG: 3077 IATA: 3077
UN proper shipping name
ADR/RID: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (4-(4-
Nitrophenoxy)benzaldehyde)
IMDG: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (4-(4-
Nitrophenoxy)benzaldehyde)
IATA: Environmentally hazardous substance, solid, n.o.s. (4-(4-Nitrophenoxy)benzaldehyde)
Transport hazard class(es)
ADR/RID: 9 IMDG: 9 IATA: 9
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: yes IMDG Marine pollutant: yes IATA: yes
Special precautions for user
Further information
EHS-Mark required (ADR 2.2.9.1.10, IMDG code 2.10.3) for single packagings and combination
packagings containing inner packagings with Dangerous Goods > 5L for liquids or > 5kg for solids.

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-硝基苯氧基)苯甲醛 在 吡啶 、 三乙烯二胺 、 sodium tetrahydroborate 、 铁粉 、 溶剂黄146 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 73.99h， 生成 (E)-methyl 3-(4-(4-aminophenoxy)phenyl)-2-methylacrylate
  参考文献：
  名称：

  Synthesis and evaluation of new diaryl ether and quinoline hybrids as potential antiplasmodial and antimicrobial agents

  摘要：

  Synthesis and bioevaluation of new diaryl ether hybridized quinoline derivatives as antiplasmodial, antibacterial and antifungal agents is reported. It was encouraging to discover that several compounds displayed 2-3 folds better efficacy than chloroquine in chloroquine-resistant K1 strain of Plasmodium falciparum. Further, a few members of the library displayed good antibacterial efficacy against gram positive strains of bacteria but none of the compounds displayed any significant antifungal activity. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.02.044
• 作为产物：
  描述：

  (4-氯甲基-苯基)-(4-硝基-苯基)-醚 生成 4-(4-硝基苯氧基)苯甲醛
  参考文献：
  名称：

  MASSARANI; NARDI; MAURI, Farmaco, Edizione Scientifica, 1963, vol. 18, p. 582 - 594

  摘要：

  DOI：

文献信息

• Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
  申请人：CoCensys, Inc.

  公开号：US20020061886A1

  公开（公告）日：2002-05-23

  This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R 1 , R 21 , R 22 and R 23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R 22 and R 23 , together with the N, form a heterocycle; A 1 and A 2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR 24 , CR 25 R 26 , C(O), NR 24 C(O), C(O)NR 24 , SO, SO 2 or a covalent bond; where R 24 , R 25 and R 26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl. The invention also is directed to the use of carbocycle and heterocycle substituted semicarbazones and thiosemicarbazones for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), for the treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy and urinary incontinence.

  这项发明涉及由式I表示的含有碳环和杂环取代的半卡巴松和硫代半卡巴松： 1 或其药学上可接受的盐或前药，其中： Y为氧或硫；R 1 ，R 21 ，R 22 和R 23 独立地为氢，烷基，环烷基，烯基，炔基，卤代烷基，芳基，氨基烷基，羟基烷基，烷氧基烷基或羧基烷基；或R 22 和R 23 ，与N一起形成一个杂环；A 1 和A 2 独立地为芳基，杂芳基，饱和或部分不饱和的碳环或饱和或部分不饱和的杂环，其中任何一个可选择地被取代；X为O、S、NR 24 、CR 25 R 26 、C(O)、NR 24 C(O)、C(O)NR 24 、SO、SO 2 或共价键；其中R 24 ，R 25 和R 26 独立地为氢，烷基，环烷基，烯基，炔基，卤代烷基，芳基，氨基烷基，羟基烷基，烷氧基烷基或羧基烷基。该发明还涉及利用含有碳环和杂环取代的半卡巴松和硫代半卡巴松治疗全脑和局部缺血后的神经损伤，治疗或预防神经退行性疾病如肌萎缩侧索硬化症（ALS），治疗和预防耳神经毒性和涉及谷氨酸毒性的眼病，以及治疗、预防或改善疼痛，作为抗癫痫药，作为抗躁狂抑郁药，作为局部麻醉药，作为抗心律失常药，以及治疗或预防糖尿病性神经病变和尿失禁。
• Atom-efficient synthesis of 2,6-diazacyclophane compounds through alcoholysis/reduction of 3-nitroarylmethylene-2,5-piperazinediones
  作者：Juan Francisco González、Elena de la Cuesta、Carmen Avendaño

  DOI：10.1016/j.tet.2008.01.047

  日期：2008.3

  dehydrodipeptides are convenient starting materials for atom-efficient synthesis of different compounds. A one-pot ring-opening/alcoholysis/hydrolysis process with 3-nitroarylmethylene-2,5-piperazinediones yielded N-3-nitroarylpyruvoylamino esters, which gave the corresponding amines by reduction of the nitro group. In the case of 2-nitroaryl compounds, an intramolecular reductive amination afforded

  现成的环状脱氢二肽是方便有效地合成不同化合物的起始原料。用3-硝基芳基亚甲基-2，5-哌嗪酮进行的一锅开环/醇解/水解过程产生N -3-硝基芳基丙酮酰氨基酯，其通过还原硝基而得到相应的胺。在2-硝基芳基化合物的情况下，分子内的还原胺化提供了N-吲哚-2-羰基氨基酯，而3-和4-硝基芳基衍生物的分子间的还原胺化使得可以合成2，6-二氮杂环烷。氨基化合物可以与氨基酸偶联以获得肽样衍生物。
• Optimization study towards more potent thiazolidine-2,4-dione IKK-β modulator: Synthesis, biological evaluation and in silico docking simulation
  作者：Ahmed Elkamhawy、Nam youn Kim、Ahmed H.E. Hassan、Jung-eun Park、Jeong-Eun Yang、Mohamed H. Elsherbeny、Sora Paik、Kwang-Seok Oh、Byung Ho Lee、Mi Young Lee、Kye Jung Shin、Ae Nim Pae、Kyung-Tae Lee、Eun Joo Roh

  DOI：10.1016/j.bioorg.2019.103261

  日期：2019.11

  synthesized, identified with different spectroscopic techniques and biologically evaluated as noteworthy IKK-β potential modulators. Successfully, new IKK-β potent modulators were obtained, including the most potent analog up-to-date 7m with IC50 value of 260 nM. A detailed structure activity relationship (SAR) was discussed and a mechanistic study for 7m was carried out indicating its irreversible inhibition

  IKK-β（核因子κB激酶亚基抑制剂）的抑制作用已被广泛报道，是治疗急性和慢性炎症性疾病，癌症和自身免疫性疾病的一种有前途的方法。最近，我们已经鉴定出一类新型的噻唑烷-2，4-二酮类化合物作为IKK-β的结构新颖的调节剂。在此，我们提出一个命中的优化研究通过模拟综合战略，旨在以获得更有效的衍生物（S），探测构效关系（SAR），并得到了引发IKK-β抑制活性合理的解释，虽然一个在硅片对接仿真研究。因此，合理设计，合成，用不同的光谱技术鉴定了一系列新的十八种噻唑烷-2,4-二酮衍生物，并在生物学上评价为值得注意的IKK-β潜在调节剂。成功获得了新的IKK-β强效调节剂，包括最强的最新模拟7m，IC 50值为260 nM。详细结构活性关系（SAR）进行了讨论和用于机理研究7米进行指示与IKK-β的不可逆抑制模式（K INACT值= 0.01（分钟-1）。此外，进行在硅片 模拟研究为这种新型调节剂与IKK-β的结合模式提供了新见解。
• Thiazolidine-2,4-dione-based irreversible allosteric IKK-β kinase inhibitors: Optimization into in vivo active anti-inflammatory agents
  作者：Ahmed Elkamhawy、Nam youn Kim、Ahmed H.E. Hassan、Jung-eun Park、Sora Paik、Jeong-Eun Yang、Kwang-Seok Oh、Byung Ho Lee、Mi Young Lee、Kye Jung Shin、Ae Nim Pae、Kyung-Tae Lee、Eun Joo Roh

  DOI：10.1016/j.ejmech.2019.111955

  日期：2020.2

  Selective kinase inhibitors development is a cumbersome task because of ATP binding sites similarities across kinases. On contrast, irreversible allosteric covalent inhibition offers opportunity to develop novel selective kinase inhibitors. Previously, we reported thiazolidine-2,4-dione lead compounds eliciting in vitro irreversible allosteric inhibition of IKK-β. Herein, we address optimization into

  选择性激酶抑制剂的开发是繁琐的任务，因为跨激酶的ATP结合位点相似。相反，不可逆的变构共价抑制作用提供了开发新型选择性激酶抑制剂的机会。以前，我们报道了噻唑烷-2,4-二酮先导化合物在体外对IKK-β产生不可逆的变构抑制作用。在本文中，我们针对体内活性抗炎药进行了优化。我们成功开发了有效的IKK-β抑制剂，其最有效的化合物引起的IC50 = 0.20μM。使用细菌内毒素脂多糖（LPS）刺激的巨噬细胞对一组活性化合物进行细胞分析，阐明了显着的体外抗炎活性。微粒体和血浆稳定性的体外评估表明，有希望的化合物7a比化合物7p更稳定。最后，已经在LPS诱导的小鼠败血性休克模型中进行了7a的体内评估，显示了其保护小鼠免受败血性休克引起的死亡的能力。因此，该研究提出了化合物7a作为新型潜在的不可逆的IKK-β变构共价抑制剂，具有经证实的体外和体内抗炎活性。
• Design, synthesis and potential 6 Hz psychomotor seizure test activity of some novel 2-(substituted)-3-{[substituted]amino}quinazolin-4(3H)-one
  作者：Praveen Kumar、Birendra Shrivastava、Surendra N. Pandeya、James P. Stables

  DOI：10.1016/j.ejmech.2011.01.009

  日期：2011.4

  Thirty new 2-(substituted)-3-[substituted]amino}quinazolin-4(3H)-one were designed and synthesized keeping in view the structural requirement of pharmacophore and evaluated for anticonvulsant activity and neurotoxicity. The anticonvulsant activity of the titled compounds was assessed using the 6 Hz psychomotor seizure test. The most active compound of the series was 3-((E)-[3-(4-chloro-3-methylp

  考虑到药效团的结构要求，设计并合成了三十种新的2-（取代的）-3-[取代的]氨基}喹唑啉-4（3 H）-1 ，并评价了其抗惊厥活性和神经毒性。使用6Hz精神运动性癫痫发作测试评估标题化合物的抗惊厥活性。该系列中活性最高的化合物是3-（（E）-[3-（4-氯-3-甲基苯氧基）苯基]亚甲基}氨基）-2-苯基喹唑啉-4（3 H）-一个PhQZ 7在小鼠中以100 mg / kg的剂量显示100％的保护（4/4，0.5 h）和75％的保护（3/4，0.25 h）。进行了计算研究，以计算药效团模式和预测药代动力学特性。在基于Lamarckian遗传算法的灵活对接研究中，标题化合物还具有与癫痫分子靶标（例如谷氨酸，GABA（A）δ和GABA（A）α-1受体）的良好结合特性。